SYNO beats the street , Peergroup Surgical
Seite 1 von 1 Neuester Beitrag: 21.08.03 23:38 | ||||
| Eröffnet am: | 25.05.03 00:11 | von: Eskimato | Anzahl Beiträge: | 12 |
| Neuester Beitrag: | 21.08.03 23:38 | von: Eskimato | Leser gesamt: | 2.088 |
| Forum: | Börse | Leser heute: | 1 | |
| Bewertet mit: |  | |||
Gruss E.
Synovis second-quarter profit up on surgical sales
WEDNESDAY, MAY 21, 2003 8:35 AM
- Reuters U.S. Company News
NEW YORK, May 21 (Reuters) - Synovis Life Technologies Inc. (SYNO) said on Wednesday its fiscal second-quarter earnings rose on higher sales of its surgical devices.
Net income rose to $1.2 million, or 12 cents a share, in the quarter ended April 30, from $766,000, or 8 cents, a year ago. Revenue rose 61 percent to $15.3 million from $9.5 million.
The St. Paul, Minnesota-based company said surgical device revenue rose 31 percent to $6.3 million, driven by higher sales of its Peri-Strips device for gastric bypass surgery.
The company also provides product engineering services, guidewires and other micro-wire and plastic devices used in cardiac rhythm management. Sales in this unit rose to $9 million from $4.6 million.
The company reaffirmed its fiscal 2003 projection that its revenue will rise as much as 37.5 percent to between $50 million and $55 million. It expects earnings per share to rise as much as 32 percent to between 38 cents to 41 cents.
© Reuters 2003. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
SYNO
16.491 -0.179
Enter Symbol:
Enter Keyword:
Also ein KGV von rund 40 bei einem Gewinnwachstum von 31%, wo soll da noch lohnendes Potenzial nach oben sein.
Bei der Unterstüzung im Bereich von 10$, da könnte sich ein Kauf wieder lohnen, aber aktuell,nee!
Grüße Reiny
Gruss E.
Chronimed Reports Fiscal 2003 Third Quarter Results; Reports Record Quarterly Revenue and Provides Guidance for Fiscal Year 2004
WEDNESDAY, APRIL 23, 2003 5:54 PM
- BusinessWire
MINNEAPOLIS, Apr 23, 2003 (BUSINESS WIRE) -- Chronimed Inc. (CHMD) reported record revenue along with strong earnings in its fiscal 2003 third quarter ended March 28, 2003. Total Company revenue was $111.8 million for the quarter, up $9.4 million or 9.2% from $102.4 million in the prior year's third quarter. Reported net income was $1.2 million, or $0.10 per share, an increase from $0.9 million or $0.07 per share in prior year's third quarter. Excluding a non-cash charge related to the vesting of restricted stock grants, net income in the current quarter was $1.6 million, or $0.12 per share.
Henry F. Blissenbach, Chronimed's Chairman and Chief Executive Officer commented, "I am pleased with our financial and operating performance in the third quarter. But I am particularly excited that during the quarter, we were named the exclusive U.S. distributor of Fuzeon(TM). This confirms our leadership position in the distribution of HIV medications and underscores the value our controlled distribution platform has with pharmaceutical manufacturers."
Blissenbach continued, "Also during the quarter, we added experienced sales leadership to direct our new sales initiatives. We are increasing our sales resources, and focusing on select diseases. We expect these initiatives and expanded sales force to be in place by the end of our fiscal 2003 fourth quarter. In addition, we signed a new three-year wholesaler agreement with Cardinal Health to cover our pharmaceutical purchases. We will begin purchasing under the new agreement, which will deliver increased overall value to Chronimed, beginning August 2003. These key accomplishments - Fuzeon distribution, new sales focus and enhanced wholesaler contract - make me confident about Chronimed's continued success."
Third quarter revenue from the Company's retail segment grew $8.0 million to $65.5 million, or 14.0%, while revenue from mail service grew $1.4 million to $46.3 million, or 3.1% over last year's third quarter.
Gross profit for the third quarter increased $1.6 million, or 13.1%, to $13.6 million compared to $12.0 million in the same period a year ago. Gross margin for the third quarter was 12.2% compared to 11.7% in the third quarter a year ago. The gross margin improvement is primarily due to improved manufacturer programs and favorable disease mix in the third quarter.
Reported operating expenses were $11.7 million, or 10.5% of revenue in the third quarter of fiscal 2003. Excluding the non-cash $0.5 million charge for the vesting of restricted stock grants from general and administrative expenses, operating expenses for the quarter were $11.2 million, or 10.0% of revenue. This compares to the prior year's operating expenses of $10.6 million, or 10.4% of revenue.
Financial Guidance for Balance of Fiscal 2003 and Fiscal 2004
The Company forecasts fiscal 2003 revenues to be approximately $430 million, and expects to report earnings of approximately $0.40 per share. The fiscal 2003 earnings guidance includes the Company's third quarter charge of approximately $0.02 per share related to the vesting of restricted stock grants. Chronimed does not expect revenue from the sale of Fuzeon to contribute materially to the Company's fourth quarter revenue and earnings as the Company invests in the early stages of the progressive distribution plan.
The Company forecasts fiscal 2004 revenue, excluding Fuzeon, to be in the range of $480 to $490 million and earnings, excluding Fuzeon, to be in the range of $0.46 to $0.48 per share. The Company believes that Fuzeon revenue and earnings will provide significant upside to this base business forecast, however, because the Fuzeon product launch is in its early stages, the Company cannot yet provide a meaningful quantification for Fuzeon to include in guidance for fiscal 2004.
Restricted Stock Grants - Third Quarter Vesting
As discussed in this earnings release, 125,000 shares of restricted stock issued to six officers in August 2002 vested during the quarter, resulting in a non-cash compensation charge of $527,000. The vesting of these stock grants has also created a personal tax liability for these officers. In order to fund the personal tax liability, these officers may be selling approximately 50,000 shares of Chronimed stock during the next few months.
reinyboy, daxbunny, kein Kauf mehr...., wie mans nimmt.
Gruss E.
Synovis Life Technologies Increases Rev And Earnings Guidance For Fiscal 2003
ST. PAUL, Minn. (Dow Jones)--Synovis Life Technologies Inc. (SYNO), citing strong surgical and interventional business, raised fiscal 2003 earnings guidance to between 43 cents and 46 cents a share, above Wall Street estimates.
In a press release Tuesday, the medical device company also said that it now expects revenue of $58 million to $59 million for the fiscal year ending Oct. 31, also beating analyst expectations.
The company had expected earnings of 38 cents to 41 cents a share on revenue of $50 million to $55 million. A survey of four analysts by Thomson First Call predicts the company will earn 42 cents a share on $57.5 million in revenue.
Synovis said that strong sales of the company's PeriStrips and interventional business growth have continued into the third quarter from the first half of the year.
The revised guidance represents a 39% to 49% gain in earnings and a 45% to 47.5% rise in revenue from fiscal 2002. In fiscal 2002, the company's diluted earnings rose 63%, while revenue rose 40%.
The company said that where its earnings fall in the range will depend on the company's ability to speed up certain business initiatives.
Last year, the company earned $3 million, or 31 cents a share, on revenue of about $40 million.
-Thomas Derpinghaus; Dow Jones Newswires; 201-938-5400
Dow Jones Newswires
07-08-031715ET
Copyright (C) 2003 Dow Jones & Company, Inc. All Rights Reserved.
Trotzdem finde ich deine Titel immer sehr interessant.
Gruss DB
Gruss E.